Siga Stock Earnings Reports

SIGA Technologies reiterated its core mission to partner with governments to strengthen preparedness against biological threats, with TPOXX positioned as a key smallpox antiviral. Financials reflected the company's characteristic quarter-to-quarter variability: Q1 had minimal product deliveries (about $1M IV deliveries to SNS and $2M manufacturing reimbursement) and R&D revenues of ~$3M, resulting in a pretax operating loss of ~$5M, net loss of ~$3M and diluted loss per share of $0.05. The company expects Q2 product revenues to include ~ $13M of oral TPOXX deliveries to an international customer plus additional IV deliveries to the SNS. SIGA reported a strong balance sheet with cash of ~$146M and no debt, and paid a $0.60 special cash dividend in April (the fifth consecutive annual special dividend). International expansion is a priority: SIGA signed an exclusive license/distribution deal with Hikma for the MENA region (SIGA to manufacture finished product; certain commercial terms confidential) and sees potential for additional global stockpiling orders. Regulatory update: CHMP reaffirmed tecovirimat (TPOXX) for smallpox, cowpox and vaccinia complications but recommended withdrawal of the MPOXX indication; SIGA is implementing required regulatory steps. Pipeline progress: pediatric IND filed and Phase 1 initiated (results expected H2), and PEP immunogenicity analysis ongoing with a target FDA PEP submission within 12 months. Management emphasized long-term outlook, domestic manufacturing, alignment with U.S. government priorities (including $27M funding in 2025 for pediatric and IV tech transfer work), and ongoing evaluation of capital deployment options including acquisitions or in-licensing.